Upregulation of prostate-specific membrane antigen after androgen- deprivation therapy

Urology

Volumn 48, Issue 2, 1996, Pages 326-334

  Wright Jr , George L ^a   Grob, B Mayer ^b   Haley, Cara ^b   Grossman, Katie ^b   Newhall, Kathy ^b   Petrylak, Daniel ^b   Troyer, John ^b   Konchuba, Alice ^b   Schellhammer, Paul F ^b   Moriarty, Richard ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CASTRATION; CLINICAL ARTICLE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSURETHRAL RESECTION;

EID: 0030219893     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00184-7     Document Type: Article

References (36)

1. 1. Emmett JL, Greene LF, and Papantoniou A: Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies, J Urol 83: 471-484, 1960.
2. 2. Labrie F: Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am 20: 845-872, 1991.
3. 3. Eisenberger MA, and Abrams JS: Chemotherapy for prostatic carcinoma. Semin Urol 6: 303-310, 1988.
4. 4. Yagoda A, and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109, 1993.
5. 5. Grignon D, and Troster M: Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate 7: 195-202, 1985.
6. 6. Murphy WM, Soloway MS, and Barrows GH: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68: 821-828, 1991.
7. 7. Horoszewicz JS, Kawinski E, and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7: 927-936, 1987.
8. 8. Wright GL Jr, Haley C, Beckett ML, and Schellhammer PF: Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1: 18-28, 1995.
9. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18: 229-241, 1991.
10. 111indium-labeled monoclonal antibody CYT-356. J Urol 152: 1952-1955, 1994.
11. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152: 1490-1495, 1994.
12. 12. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mithell E, et al: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 10: 45-54, 1992.
13. 13. Troyer JK, Beckett ML, and Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558, 1995.
14. 14. Stamey TA, Kabalin JN, Ferrai M, and Yang N: Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 141: 1088-1090, 1989.
15. 15. Miller JI, Ahmann FR, Drach GW, Emerson SS, and Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
16. 16. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP, and Braswell NT: Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol 153: 1860-1865, 1995.
17. 17. Hsieh J-T, Wu H-C, Gleave ME, von Eschenbach AC, and Chung LWK: Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 53: 2852-2857, 1993.
18. 18. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, and Chung LWK: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581, 1994.
19. 19. Montgomery BT, Young CY-F, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, and Tindall DJ: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21: 63-73, 1992.
20. 20. Israeli RS, Powell CT, Corr JG, Fair WR, and Heston WDW: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994.
21. 21. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkmann AO, and Trapman J: The promoter of the prostatespecific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5: 1921-1930, 1991.
22. 22. Knabbe C, Klein HR, Zugmaier G, Voigt KD: Hormone regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem 47: 137-142, 1993.
23. 23. Kantoff PW: Advances in nonsurgical management of prostate cancer. Adv Oncol 9: 24-29, 1993.
24. 24. Petrylak DP, Scher HI, Le Z, Myers CE, and Geller NL: Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70: 2870-2878, 1994.
25. 25. Kyprianou N, and Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988.
26. 26. Miyashita T, and Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
27. 27. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, and Gelmann EP: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55: 735-738, 1995.
28. 28. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsiesh J-T, Tu S-M, and Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
29. 29. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, and Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
30. 30. Liu AY, Corey E, Bladou F, Lange PH, and Vessella RL: Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 65: 85-89, 1995.
31. 31. Murphy GP, Beckley S, Brady MF, Chu TM, de Kernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264-1272, 1983.
32. 32. Pummer K: Epirubicin plus flutamide and orchiectomy in previously untreated advanced prostatic cancer. Semin Oncol 18: 26-28, 1991.
33. 33. Dawson NA, Wilding G, Weiss RB, McLeod DG, Linehan WM, Grank JA, Jacob JL, and Gelmann EP: A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer 69: 213-218, 1992.
34. 34. Warters RL: Radiation-induced apoptosis in a murine T-cell hybridoma. Cancer Res 52: 883-890, 1992.
35. 35. Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, and Fuks Z: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29: 755-761, 1994.
36. 36. Axelrod HR, Gilman SC, D'Aleo CJ, Petrylak D, Reuter V, Gulfo JV, Saad A, Cordon-Cardo C, and Scher HI: Preclinical results and human immunohistochemical studies with 90Y-CYT-356: a new prostatic cancer therapeutic agent (abstract 596). Proceedings of the 87th Annual Meeting of the American Urological Association, 1992, p 361A.